Review



total dnapkcs  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc total dnapkcs
    Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of <t>p-DNAPKcs,</t> total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.
    Total Dnapkcs, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 87 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/total+dnapkcs/DNA-PKcs+Mouse+mAb/pmc07027396-54-10-12
    Average 95 stars, based on 87 article reviews
    total dnapkcs - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells"

    Article Title: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells

    Journal: Frontiers in Endocrinology

    doi: 10.3389/fendo.2020.00035

    Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of p-DNAPKcs, total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.
    Figure Legend Snippet: Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of p-DNAPKcs, total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.

    Techniques Used: Quantitative RT-PCR, Expressing, Western Blot

    Related Articles

    Quantitative RT-PCR:

    Article Title: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
    Article Snippet: Proteins were detected using antibodies for phospho-DNAPKcs (Abcam ab124918, 1:1,000), total DNAPKcs (CST 12311, 1:1,000), androgen receptor (Millipore 06-680, 1:1,000), GAPDH (CST 2118, 1:1,000), and β-Actin (8H10D10, Cell Signaling 12262S, 1:50,000).

    Expressing:

    Article Title: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
    Article Snippet: Proteins were detected using antibodies for phospho-DNAPKcs (Abcam ab124918, 1:1,000), total DNAPKcs (CST 12311, 1:1,000), androgen receptor (Millipore 06-680, 1:1,000), GAPDH (CST 2118, 1:1,000), and β-Actin (8H10D10, Cell Signaling 12262S, 1:50,000).

    Western Blot:

    Article Title: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
    Article Snippet: Proteins were detected using antibodies for phospho-DNAPKcs (Abcam ab124918, 1:1,000), total DNAPKcs (CST 12311, 1:1,000), androgen receptor (Millipore 06-680, 1:1,000), GAPDH (CST 2118, 1:1,000), and β-Actin (8H10D10, Cell Signaling 12262S, 1:50,000).



    Similar Products

    total dnapkcs  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc total dnapkcs
    Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of <t>p-DNAPKcs,</t> total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.
    Total Dnapkcs, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/total+dnapkcs/DNA-PKcs+Mouse+mAb/pmc07027396-54-10-12
    Average 95 stars, based on 1 article reviews
    total dnapkcs - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of p-DNAPKcs, total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.

    Journal: Frontiers in Endocrinology

    Article Title: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells

    doi: 10.3389/fendo.2020.00035

    Figure Lengend Snippet: Differential effects on AR and AR targets with enzalutamide and seviteronel treatment. AR+ TNBC cells were treated with 5 μM enzalutamide or seviteronel ± 10 nM DHT. RT-qPCR was used to assess mRNA expression of (A) AR , (B) AQP3 , and (C) SEC14L2 in MDA-MB-453 cells. (D) Protein levels of p-DNAPKcs, total DNAPKcs, and AR were measured by immunoblot in MDA-MB-453 cells. Gene expression data represent mean ± SEM for three independent experiments, and immunoblots are representative of triplicate experiments. NS, p is not significant, * p < 0.05, ** p < 0.01.

    Article Snippet: Proteins were detected using antibodies for phospho-DNAPKcs (Abcam ab124918, 1:1,000), total DNAPKcs (CST 12311, 1:1,000), androgen receptor (Millipore 06-680, 1:1,000), GAPDH (CST 2118, 1:1,000), and β-Actin (8H10D10, Cell Signaling 12262S, 1:50,000).

    Techniques: Quantitative RT-PCR, Expressing, Western Blot